KN046 （PD-L1/CTLA4 BsAb）

DRUG2 trials

Sponsors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Zhejiang Raygene Pharmaceuticals Co., Ltd

Conditions

Advanced HCCColorectal Cancer with Hepatic Metastases

Phase 1

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

TerminatedNCT04601610

Jiangsu Alphamab Biopharmaceuticals Co., LtdAdvanced HCC

Start: 2021-06-07End: 2022-05-30Updated: 2022-10-28

Phase 2

TATE and KN046 in MCRC

TerminatedNCT06834399

Zhejiang Raygene Pharmaceuticals Co., LtdColorectal Cancer with Hepatic Metastases

Start: 2023-04-27End: 2025-01-09Updated: 2025-02-19